Evidence map›Paper›PMID 41757489›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2026

Chemotherapeutic Potential of Fluorouracil-Platinum (IV) Prodrugs Against Cisplatin-Resistant Colorectal Cancer Cells.

Maria George Elias, Aleen Khoury, Shadma Fatima, Timothy J Mann, Shawan Karan, Meena Mikhael, Paul de Souza, Christopher P Gordon, Kieran F Scott, Janice R Aldrich-Wright

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Maria George EliasFaculty of Engineering, Computing and Science, Western Sydney University, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-1478-7006
Aleen KhouryFaculty of Engineering, Computing and Science, Western Sydney University, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-7139-9536
Shadma FatimaMedical Oncology, Ingham Institute for Applied Medical Research, Liverpool Hospital, Liverpool, New South Wales, Australia.ORCID https://orcid.org/0000-0002-3583-1301
Timothy J MannFaculty of Health, School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-2272-7011
Shawan KaranFaculty of Engineering, Computing and Science, Western Sydney University, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-9775-1932
Meena MikhaelMass Spectrometry Facility, Western Sydney University, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0003-4355-4954
Paul de SouzaNepean Clinical School, Faculty of Medicine and Health, University of Sydney, Kingswood, New South Wales, Australia.ORCID https://orcid.org/0000-0002-7380-1170
Christopher P GordonFaculty of Engineering, Computing and Science, Western Sydney University, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0001-7583-5609
Kieran F ScottFaculty of Health, School of Medicine, Western Sydney University, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-6012-4107
Janice R Aldrich-WrightFaculty of Engineering, Computing and Science, Western Sydney University, Sydney, New South Wales, Australia.ORCID https://orcid.org/0000-0002-6943-6908

Funding

School of Medicine, Western Sydney UniversityWestern Sydney University
6 · The paper itself

Abstract

Fluorouracil-platinum(IV) prodrugs represent a novel class of multimechanistic chemotherapeutics with enhanced anticancer potential. The prodrugs Pt

Indexed as

Antineoplastic AgentsCisplatinColorectal NeoplasmsFluorouracilOrganoplatinum CompoundsPlatinumProdrugsApoptosisCell CycleCell Line, TumorCell SurvivalDrug Resistance, NeoplasmHumansMembrane Potential, MitochondrialReactive Oxygen SpeciesAntineoplastic AgentsCisplatinFluorouracilOrganoplatinum CompoundsPlatinumProdrugsReactive Oxygen Speciesapoptosiscytoskeletoncytotoxicityfluorouracilplatinum(II)platinum(IV)

Identifiers

PMID41757489
PMCPMC13472338

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.